QRG Capital Management Inc. Acquires 125,612 Shares of Haleon PLC Sponsored ADR (NYSE:HLN)

QRG Capital Management Inc. grew its stake in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 38.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 451,968 shares of the company's stock after purchasing an additional 125,612 shares during the quarter. QRG Capital Management Inc.'s holdings in Haleon were worth $4,651,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Brighton Jones LLC bought a new position in Haleon in the fourth quarter worth about $187,000. Savant Capital LLC raised its position in shares of Haleon by 99.2% in the 4th quarter. Savant Capital LLC now owns 26,393 shares of the company's stock worth $252,000 after acquiring an additional 13,142 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Haleon by 11.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 28,474 shares of the company's stock worth $269,000 after acquiring an additional 2,914 shares in the last quarter. Valeo Financial Advisors LLC raised its position in shares of Haleon by 11.7% in the 4th quarter. Valeo Financial Advisors LLC now owns 20,453 shares of the company's stock worth $195,000 after acquiring an additional 2,141 shares in the last quarter. Finally, Principal Securities Inc. raised its holdings in Haleon by 46.4% in the fourth quarter. Principal Securities Inc. now owns 78,878 shares of the company's stock worth $752,000 after purchasing an additional 24,997 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on HLN. Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. BNP Paribas Exane raised shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 target price for the company in a research note on Tuesday, May 27th. HSBC reaffirmed a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Finally, Hsbc Global Res lowered Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $12.33.

Haleon Stock Down 0.5%

NYSE:HLN traded down $0.06 on Friday, reaching $10.40. 14,895,917 shares of the stock traded hands, compared to its average volume of 9,121,184. The company has a market capitalization of $46.77 billion, a price-to-earnings ratio of 26.65, a PEG ratio of 2.96 and a beta of 0.31. The company has a current ratio of 0.98, a quick ratio of 0.78 and a debt-to-equity ratio of 0.53. The company's fifty day simple moving average is $10.69 and its 200 day simple moving average is $10.10. Haleon PLC Sponsored ADR has a 12 month low of $8.25 and a 12 month high of $11.42.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.